Combining innovative science, leading technology, and unmatched know-how to create novel medicines.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Our Science
Our lead program targets interleukin-11, a cytokine which is a central mediator of fibrosis and plays a key role in the tumor microenvironment of certain cancers.
Our Pipeline
Lassen is applying industry-leading antibody technologies to create a pipeline of breakthrough therapeutics.
Our team has a proven track record of building robust antibody development platforms and pipelines and is guided by a set of meaningful and inspirational core values. We are:
- Innovative and adapt to challenges
- Honest and communicate transparently
- Collaborative and treat everyone with respect
- Focused on people – our team, our collaborators, and patients
- Passionate about creating life-improving medicines
-
- LASN01 is a potent inhibitor of IL-11 signaling
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- LASN01 is rapidly advancing toward clinical evaluation
-
- Lassen selected for oral presentation at ATS scientific sessions and will be featured at the ATS Respiratory Innovation Summit
- Lassen SAB member Cory Hogaboam, Ph.D. from Cedars-Sinai, to present data on IL-11 in idiopathic pulmonary fibrosis at ATS scientific sessions
-
18 November 2021 | Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer
Dr. Arora brings deep expertise in innovative biopharmaceutical development and experience in inflammation and immunology > Full Story